Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

April 27, 2023

Primary Completion Date

September 23, 2024

Study Completion Date

June 30, 2028

Conditions
Tenosynovial Giant Cell TumorPigmented Villonodular SynovitisGiant Cell Tumor of Tendon Sheath
Interventions
DRUG

Pimicotinib(ABSK021)

capsule

DRUG

Placebo

capsule

Trial Locations (40)

2333

Leiden University Medical Center, Leiden

14263

Roswell Park Comprehensive Cancer Center, Buffalo

27710

Duke University Medical Center, Durham

28040

Fundacion Jimenez Diaz, Madrid

43210

The Ohio State University, Columbus

44195

The Cleveland Clinic Foundation, Cleveland

48202

Henry Ford Health System, Detroit

77030

The University of Texas M.D. Anderson Cancer Center, Houston

90212

Precision NextGen Oncology, Beverly Hills

98109

Fred Hutchinson Cancer Center, Seattle

Unknown

McGill University Health Center, Montreal

Princess Margaret Cancer Center, Toronto

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Peking University People's Hospital, Beijing

The First Affiliated Hospital of Fujian Medical University, Fuzhou

Guangdong Provincial People's Hospital, Guangzhou

The First Affiliated Hospital of Jinan University, Guangzhou

The First Affiliated Hospital, Sun Yat-sen University, Guangzhou

The Affiliated Hospital of Guizhou Medical University, Guiyang

Henan Cancer Hospital, Zhengzhou

The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi

Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan Provincial People's Hospital, Changsha

The Second Xiangya Hospital of Central South University, Changsha

Nanjing Drum Tower hospital, Nanjing

Liaoning Cancer Hospital&Institute, Shenyang

Weifang People's Hospital, Weifang

Shanghai General Hospital, Shanghai

The Second Hospital of Shanxi Medical University, Taiyuan

Xi'an Honghui Hospital, Xi’an

West China Hospital Sichuan University, Chengdu

The First Affiliated Hospital of Xinjiang Medical University, Ürümqi

The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou

Zhejiang Cancer Hospital, Hangzhou

Beijing Jishuitan Hospital, Beijing

IRCCS Istituto Ortopedico Rizzoli, Bologna

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

Ospedale di Prato, Prato

Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw

Hospital Universitari Vall d'Hebron, Barcelona

Sponsors
All Listed Sponsors
lead

Abbisko Therapeutics Co, Ltd

INDUSTRY